Connective tissue diseases (CTDs) are a heterogeneous group of disorders that share
certain clinical presentations and a disturbed immunoregulation, leading to autoantibody …

Elective therapeutic approaches are required since recurrent thrombosis remains a major
challenge in the management of antiphospholipid syndrome (APS) despite an efficient …

The American Society for Apheresis (ASFA) JCA Special Issue Writing Committee is
charged with reviewing, updating and categorizating indications for therapeutic apheresis …

Abstract The American Society for Apheresis (ASFA) Apheresis Applications Committee is
charged with a review and categorization of indications for therapeutic apheresis. Beginning …

Abstract Annexin A5 (AnxA5) is a potent anticoagulant protein that crystallizes over
phospholipid bilayers (PLBs), blocking their availability for coagulation reactions …

The relapse rate in antiphospholipid syndrome (APS) remains high, ie around 20%–21% at
5 years in thrombotic APS and 20–28% in obstetrical APS [2, 3]. Hydroxychloroquine (HCQ) …

Antiphospholipid syndrome (APS) is an autoimmune disease defined by the presence of
arterial or venous thrombotic events and/or pregnancy morbidity in patients who test positive …

The use of the conventional APS treatment (the combination of low-dose aspirin and LMWH)
dramatically improved the obstetrical prognosis in primary obstetrical APS (OAPS). The …

Satisfactory results have not yet been obtained in therapy for secondary prevention in
ischemic stroke patients with antiphospholipid syndrome (APS). We therefore compared …

Objectives To describe the pulmonary involvement in patients with catastrophic
antiphospholipid syndrome (CAPS), focusing on its relationship with extrapulmonary …